Venenum BioDesign Competitors and Similar CompaniesClear all

Meitheal Pharmaceuticals's competitors and similar companies include Atossa Therapeutics, Briacell and Zenopharm.
Meitheal Pharmaceuticals
Meitheal Pharmaceuticals
Meitheal Pharmaceuticals is a pharmaceutical development and manufacturing company.
Atossa Therapeutics
Atossa Therapeutics
Atossa Therapeutics (formerly Atossa Genetics) is a pharmaceutical company focused on the development of breast cancer therapeutics.
Briacell
Briacell
Briacell is a clinical-stage biotech company that focuses on immuno-oncology and develops personalized immunotherapy for cancer.
Zenopharm
Zenopharm
Zenopharm is a pharmaceutical company developing therapeutic solutions for the treatment of breast cancer.
Founding Date
Founding Date
2017
Founding Date
2009
Founding Date
2004
Founding Date
2012
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Chicago, US HQ
Locations
Seattle, US HQ
Seattle, US
Locations
West Vancouver, CA HQ
Berkeley, US
New York, US
Locations
HQ
Employees
Employees
1329% increase
Employees
667% decrease
Employees
16
Employees
N/A
Valuation ($)
Valuation ($)
N/A
Valuation ($)
182.3 m
Valuation ($)
30.2 m
Valuation ($)
N/A

Financial

Net income
Net income
N/A
Net income
($34.8m) (FY, 2025)
Net income
($26.6m) (FY, 2025)
Net income
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 7.6m
Total funding raised
N/A
Total funding raised
$ 18.3m
For sources of this data, please see the company profile

View Company Profiles

Atossa Therapeutics
HQ
Seattle, US
Employees
6

Atossa Therapeutics (formerly Atossa Genetics) is a pharmaceutical company focused on the development of breast cancer therapeutics.

View company
Briacell
HQ
West Vancouver, CA
Employees
16

Briacell is a clinical-stage biotech company that focuses on immuno-oncology and develops personalized immunotherapy for cancer.

View company
Zenopharm
HQ

Zenopharm is a pharmaceutical company developing therapeutic solutions for the treatment of breast cancer.

View company